Synergy Innovation
Daily close in US$ at the latest USD/KRW close. Source: KRX via FinanceDataReader.
Synergy Innovation makes microbial culture media, the nutrient-rich substances used to grow and detect bacteria in laboratory and pharmaceutical-manufacturing settings.
It supplies these products, along with related in-vitro diagnostic reagents, to hospitals, testing centres, and pharmaceutical companies across South Korea. Listed on KOSDAQ, Korea's tech and small-cap exchange, the company operates across three business divisions, biotechnology, medical, and health functional foods, with the medical division generating the majority of its revenue.
Summary is AI-generated and may contain errors · figures from DART filings
The consolidated group comprises seven entities in total, including a drug-discovery subsidiary, Neurobiozen, that focuses on new-medicine research and development.
Synergy Innovation in five facts
What does Synergy Innovation do?
Synergy Innovation makes microbial culture media, the nutrient-rich substances used to grow and detect bacteria in laboratory and pharmaceutical-manufacturing settings.
Where is Synergy Innovation listed and in which sector?
Synergy Innovation (Korean name: 시너지이노베이션) trades under KRX code 048870 on KOSDAQ, the Korea Exchange's board for smaller and growth companies. It is classified in the Health Care sector, Medical Devices.
How large is Synergy Innovation?
Its market capitalisation was US$98.2M on 2026-10-21, which puts it in this site's small-cap group. US$ amounts are converted from won at 1 USD ≈ ₩1,325 (2026-10-21).
What were Synergy Innovation's latest annual revenue and operating profit?
For fiscal year 2025, Synergy Innovation reported revenue of US$85.3M, operating profit of US$14.5M and net income of US$8.4M, per its annual report on DART (data retrieved from DART on 2026-09-17). Revenue was up 24.8% on the previous year.
Where does this data come from?
Financial statements and filings come from DART, Korea's official corporate-filing system. Share prices, market capitalisation and trading status come from KRX. Company summaries are AI-generated from the filings and may contain errors; financial figures are mapped directly from DART.
Data sources and last updated
- Filings and financial statements
- DART (dart.fss.or.kr), Korea's official corporate-filing system
- Prices, market cap, trading status
- KRX (Korea Exchange), via FinanceDataReader
- Latest annual financials
- Fiscal year 2025, data retrieved from DART on 2026-09-17
- Share price and market cap
- Close of 2026-10-21
- Currency
- US$, converted from won at 1 USD ≈ ₩1,325 (2026-10-21 close)
- Company data updated
- 2026-10-21
- Company summary
- AI-generated from filings; may contain errors. Information only, not investment advice.
- [Amended] Material event report (equity disposal)Sep 30
- Early redemption of convertible bonds (incl. overseas CBs)Capital raise · Sep 22
- [Amended] Material event report (equity disposal)Sep 9
- Early redemption of convertible bonds (incl. overseas CBs)Capital raise · Jun 23
- Early redemption of convertible bonds (incl. overseas CBs)Capital raise · Jun 22
- Early redemption of convertible bonds (incl. overseas CBs)Capital raise · Mar 23
- Change of 30% or more in revenue or profit/loss structure (15% for large companies)
Synergy Innovation reported consolidated results for FY2025: revenue of US$76.6M (+24.8% year on year), operating profit of US$13.1M (+19.9% year on year) and net income of US$7.6M (−38.2% year on year).
Earnings · Mar 12